Primary-source record
Tanabe Pharma submitted a marketing authorization application to Japan's MHLW for ZYNLONTA (loncastuximab tesirine) in r/r DLBCL after >=2 lines of therapy. Multiple ZYNLONTA abstracts, including full Phase 3 LOTIS-5 and Phase 1b LOTIS-7 results, were accepted for oral presentation at ASH in December 2026. This earnings release recaps these and other recent operational updates.
EX-99.1 2 adct-20260930pressrelease.htm EX-99.1 Document Exhibit 99.1 ADC Therapeutics Reports Third Quarter 2026 Financial Results and Provides Operational Updates Third quarter 2026 net product revenue of $21 million; cash and cash equivalents of $189.2 million as of September 30, 2026 Strategic financial restructuring strengthens balance sheet, extending expected cash runway into 2029 Abstracts accepted for presentation at ASH 2026, highlighting ZYNLONTA's potential across multiple B-cell malignancies Tanabe’s marketing authorization application filing and sublicensing in Japan support anticipated regulatory and commercial milestones for ADC Therapeutics LAUSANNE, Switzerland, November 9, 2026 – ADC Therapeutics SA (NYSE: ADCT) today reported full financial results for the third quarter ended September 30, 2026, and provided recent operational updates. “During the third quarter, we made meaningful progress toward strengthening ADC Therapeutics' balance sheet and increasing strategic optionality while advancing clinical opportunities for ZYNLONTA®,” said Ameet Mallik, Chief Executive Officer of ADC Therapeutics. “In addition, we continue to deliver on sales while focusing on opportunities to expand ZYNLONTA's role in the treatment of B-cell malignancies to drive growth. With multiple abstracts accepted for presentation at ASH, including the full results from LOTIS-7, we look forward to highlighting the breadth of ZYNLONTA's clinical potential at this meeting.” “As
ADC Therapeutics Announces Financial Restructuring and ASH 2026 Data Presentations for ZYNLONTA